MOLECULAR BASIS OF SQUAMOUS DIFFERENTIATION AND NEOPLASIA IN SKIN & ORAL TISSUES
MOLECULAR BASIS OF SQUAMOUS DIFFERENTIATION AND NEOPLASIA IN SKIN & ORAL TISSUES
批准号:
6289712
负责人:
Jorge Silvio Gutkind
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The vast majority of cancers arising in the oral cavity are squamous cell carcinomas. The Keratinocyte Biology Group was established in January, 1998 to elucidate mechanisms of squamous cell differentiation and the biochemical alterations contributing to the neoplastic phenotype and malignant conversion. Our work has utilized keratinocytes of murine epidermis and both in vitro and in vivo approaches to dissect the stages of differentiation and neoplastic progression. The p53 tumor suppressor gene is mutated or inactivated in a majority of human cancers, including those of the oral cavity, and our studies have focused on elucidating the function and mechanism of action of this gene product in keratinocyte biology. The cyclin dependent kinase inhibitor WAF1, a downstream target of p53 mediated gene transcription, is believed to be an effector of tumor suppression by p53. We have explored the role of the WAF1 gene product in multistep carcinogenesis, and using both in vivo and in vitro models have demonstrated that loss of WAF1 is not sufficient to explain the malignant phenotype of p53 null tumors; thus, other features of p53 beside transcriptional activation of the WAF1 gene are necessary for its tumor suppressor function. In addition, by differential display analysis we have identified a novel p53 regulated gene that is also part of the TNF-alpha pathway and have found that this overexpression of this gene product rapidly induces keratinocyte cell death. Because the p53 protein is inactivated in a majority of cancers arising in the oral cavity, elucidating this pathway should help to clarify the etiology of oral carcinogenesis and suggest novel therapeutic interventions. - keratinocyte, squamous differentiation, epidermal carcinogenesis, tumor suppression
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Signal Transduction by PI3K/mTOR
-
批准号:10182868
-
项目类别:
-
资助金额:$48.31万
-
财政年份:2021
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Signal Transduction by PI3K/mTOR
-
批准号:10578841
-
项目类别:
-
资助金额:$48.35万
-
财政年份:2021
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Signal Transduction by PI3K/mTOR
-
批准号:10366013
-
项目类别:
-
资助金额:$47.86万
-
财政年份:2021
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
-
批准号:10536607
-
项目类别:
-
资助金额:$49.0万
-
财政年份:2019
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Multidisciplinary Educational Approach to Reducing Cancer Disparities
-
批准号:10683194
-
项目类别:
-
资助金额:$35.2万
-
财政年份:2019
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Multidisciplinary Educational Approach to Reducing Cancer Disparities
-
批准号:10246272
-
项目类别:
-
资助金额:$34.6万
-
财政年份:2019
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Multidisciplinary Educational Approach to Reducing Cancer Disparities
-
批准号:10002204
-
项目类别:
-
资助金额:$46.91万
-
财政年份:2019
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy
-
批准号:10439800
-
项目类别:
-
资助金额:$46.24万
-
财政年份:2018
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy
-
批准号:10214590
-
项目类别:
-
资助金额:$46.71万
-
财政年份:2018
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers
-
批准号:10115173
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2018
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers
-
批准号:10461025
-
项目类别:
-
资助金额:$83.81万
-
财政年份:2018
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy
-
批准号:9753204
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2018
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy
-
批准号:9977696
-
项目类别:
-
资助金额:$46.59万
-
财政年份:2018
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers
-
批准号:10237372
-
项目类别:
-
资助金额:$84.93万
-
财政年份:2018
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Targeting Signaling Vulnerabilities for Oral Cancer Prevention
-
批准号:10540202
-
项目类别:
-
资助金额:$47.51万
-
财政年份:2017
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Area C: Genome-wide identification and targeting of resistance to cancer therapy
-
批准号:9482962
-
项目类别:
-
资助金额:$21.62万
-
财政年份:2017
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Targeting Signaling Vulnerabilities for Oral Cancer Prevention
-
批准号:10647799
-
项目类别:
-
资助金额:$47.51万
-
财政年份:2017
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Molecular Mechanisms of Growth Control and Carcinogenesis
-
批准号:6104616
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Jorge Silvio Gutkind
-
依托单位:
Oral Carcinogenesis
-
批准号:8929672
-
项目类别:
-
资助金额:$180.53万
-
财政年份:--
-
负责人:Jorge Silvio Gutkind
-
依托单位:
ORAL CARCINOGENESIS
-
批准号:6161812
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Jorge Silvio Gutkind
-
依托单位:
国内基金
海外基金
蒺藜苜蓿细胞周期蛋白依赖性激酶(cyclin-dependent kinase)对根瘤发育的功能研究
-
批准号:31100871
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2011
-
负责人:何恒斌
-
依托单位: